Filgotinib Shows Efficacy in Noninfectious Uveitis, But More Data Are Needed
- Posted on: Aug 13 2024
- Leave a response
Filgotinib, an oral preferential Janus kinase 1 inhibitor, is currently approved to treat certain rheumatologic conditions in several countries outside the United States. The HUMBOLDT trial studied its potential efficacy in treating noninfectious uveitis.
Source: AAO
Posted in: Uncategorized
